Molnupiravir for Treatment of Adults with Mild or Moderate COVID-19: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ya Gao,Ming Liu,Zhifan Li,Jianguo Xu,Junhua Zhang,Jinhui Tian

DOI: https://doi.org/10.1016/j.cmi.2023.04.014

2023-01-01

Abstract:BACKGROUND:The effects of molnupiravir in treating patients with non-severe COVID-19 remain uncertain. OBJECTIVES:To evaluate the efficacy and safety of molnupiravir in adult patients with mild or moderate COVID-19. DATA SOURCES:PubMed, Embase, CENTRAL, Web of Science, and WHO COVID-19 database up to 27 December 2022. STUDY ELIGIBILITY CRITERIA:Randomized controlled trials with no language restrictions. PARTICIPANTS:Adults with mild or moderate COVID-19. INTERVENTIONS:Molnupiravir against standard care or placebo. ASSESSMENT OF RISK OF BIAS:We used a revision of RoB-2 criteria. METHODS OF DATA SYNTHESIS:Outcomes were mortality, hospital admission, viral clearance, time to viral clearance, time to symptom resolution or clinical improvement, any adverse events, and serious adverse events. We performed DerSimonian-Laird random-effects meta-analyses to summarize the evidence and evaluated the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. RESULTS:Nine randomized controlled trials enrolling 30 472 patients proved eligible. Majority of patients were outpatients, with a mean age ranging from 35 to 56.6 years. In adult patients with mild or moderate COVID-19, molnupiravir probably reduces mortality (relative risk [RR], 0.43; 95% CI, 0.20-0.94; risk difference [RD], 0.1% fewer; moderate certainty) and the risk of hospital admission (RR, 0.67; 95% CI, 0.45-0.99; RD, 1.4% fewer; moderate certainty) and may reduce time to viral clearance (mean difference, -1.81 days; 95% CI, -3.31 to -0.31; low certainty) and time to symptom resolution or clinical improvement (mean difference, -2.39 days; 95% CI, -3.71 to -1.07; low certainty). Molnupiravir probably increases the rate of viral clearance (RR, 3.47; 95% CI, 2.43-4.96; RD 16.1% more; moderate certainty) at 7 days (±3 days) and likely does not increase serious adverse events (RR, 0.84; 95% CI, 0.61-1.15; RD 0.1% fewer; moderate certainty). CONCLUSIONS:In adult patients with mild or moderate COVID-19, molnupiravir likely reduces mortality and risk of hospital admission probably without increasing serious adverse events.